Skip to main content
NRIX
NASDAQ Life Sciences

Sanofi Kills Phase 1 STAT6 Degrader, Wiping Out Nurix's SAR448272 Milestones

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$17.884
Mkt Cap
$2.821B
52W Low
$11.67
52W High
$28.23
52W Position info
53% above low
Off High info
37% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

NRIX sits 53% above its 52-week low of $11.67.

Summary

Sanofi discontinued the Phase 1 trial of SAR448272 and terminated the program outright, so Nurix will collect none of the future development, regulatory or commercial milestones or royalties tied to it. The release gives no dollar value or timing for the foregone payments, so the hit is to partnered-pipeline optionality rather than to near-term cash. Nurix says its runway guidance is unchanged: $1.1B in cash and securities at August 31, 2026 funds operations into the second half of 2029. That cushion is what keeps this from being a thesis-breaker — the company's own Phase 3 asset bexobrutideg and the rest of the Sanofi-licensed portfolio remain eligible for payments, though Sanofi decides whether to advance them. This lands alongside the 8-K filed the same evening and follows the October 5 news that Gilead extended a Nurix research term by two years, a reminder that partner decisions cut both ways.

At the time of this announcement, NRIX was trading at $17.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $11.67 to $28.23. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

NRIX - Latest Insights

NRIX
Nov 03, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.03
Real-time Price: $12.89 info
Change: -$9.15 (-42%) info
Market Cap: $1.408B info
NRIX
Oct 13, 2026, 6:21 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $22.50
Real-time Price: $12.89 info
Change: -$9.62 (-43%) info
Market Cap: $1.408B info
NRIX
Oct 13, 2026, 6:19 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.50
Real-time Price: $12.89 info
Change: -$9.62 (-43%) info
Market Cap: $1.408B info
NRIX
Oct 12, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $23.06
Real-time Price: $12.89 info
Change: -$10.18 (-44%) info
Market Cap: $1.408B info
NRIX
Oct 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.96
Real-time Price: $12.89 info
Change: -$10.08 (-44%) info
Market Cap: $1.408B info